8-KEarnings & ResultsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Aug 1, 2024)

Filed August 1, 2024For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 1, 2024, to report its financial and operating results for the second quarter ended June 30, 2024. The key information is contained within the press release furnished as Exhibit 99.1 to the filing. Investors should review this press release for detailed insights into the company's performance during the quarter, including revenue generation, profit margins, and strategic updates. This filing serves as the official notification of REGN's Q2 2024 performance. While the 8-K itself is brief, the attached press release is the primary source of information for understanding the company's financial health, operational achievements, and outlook. Investors are encouraged to access and analyze Exhibit 99.1 for a comprehensive understanding of the company's recent results and any forward-looking statements.

Key Highlights

  • 1Filing reports Q2 2024 financial and operating results.
  • 2Key information is detailed in the press release furnished as Exhibit 99.1.
  • 3The 8-K itself serves as a notification of the results release.
  • 4Investors should consult Exhibit 99.1 for detailed financial and operational data.
  • 5The filing was made on August 1, 2024, with an event date of July 31, 2024.
  • 6Information furnished under Item 2.02 is not deemed 'filed' for certain SEC purposes unless expressly incorporated by reference.

Frequently Asked Questions

The detailed Q2 2024 financial and operating results are provided in the press release furnished as Exhibit 99.1 to this 8-K filing.

This 8-K filing formally announces Regeneron's financial and operational performance for the second quarter of 2024. It directs investors to the accompanying press release for the specific details of these results.

The information included in Item 2.02 of the 8-K, including the press release, is furnished to the SEC and is generally not considered 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 or incorporated by reference into other filings, unless explicitly stated otherwise in a future filing.